

Part VI: Summary of the Risk Management Plan

Summary of risk management plan for Brinzolamide/Timolol Zentiva (Brinzolamide/Timolol)

This is a summary of the risk management plan (RMP) for Brinzolamide/Timolol Zentiva. The RMP details important risks of Brinzolamide/Timolol Zentiva, how these risks can be minimised, and how more information will be obtained about Brinzolamide/Timolol Zentiva's risks and uncertainties (missing information).

Brinzolamide/Timolol Zentiva's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Brinzolamide/Timolol Zentiva should be used.

Important new concerns or changes to the current ones will be included in updates of Brinzolamide/Timolol Zentiva's RMP.

I. The medicine and what it is used for

Brinzolamide/Timolol Zentiva is indicated to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction (see SmPC for the full indication). One mL of suspension (eye drops) contains 10 mg brinzolamide and 5 mg timolol (as timolol maleate). It contains Brinzolamide/Timolol as the active substance and it is applied by ophthalmic route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Brinzolamide/Timolol Zentiva, together with measures to minimise such risks and the proposed studies for learning more about Brinzolamide/Timolol Zentiva's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of Brinzolamide/Timolol Zentiva are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Brinzolamide/Timolol Zentiva. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to

information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none">• Respiratory disorders• Cardiovascular disorders• Corneal decompensation• Metabolic acidosis
Important potential risks	<ul style="list-style-type: none">• Corneal damage due to long term use of preserved eye drops
Missing information	<ul style="list-style-type: none">• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Brinzolamide/Timolol Zentiva.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Brinzolamide/Timolol Zentiva.